In SCLC patients, a combination of serum biomarkers like nucleosomes, NSE, ProGRP and CYFRA 21-1 achieved up to 47% sensitivity at 95% specificity to predict insufficient response to first-line chemotherapy [98]. The gene discussed is ENO2; the disease is small cell lung carcinoma.